$6.79+1.0%Nov 9 close
Figures through September 30, 2026, from the 10-Q filed November 10, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$12.1M | -$14.4M | +16.14% |
| Profit per share | -$0.11 | -$0.28 | +60.71% |
| Free Cash Flow | -$8.4M | -$2.2M | -279.64% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Achieve Life Sciences, Inc. reported on November 10, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Becoming AchieveRx, The Quit Company, reflects our shift from a clinical-stage company to one preparing to launch what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
AchieveRx is a late-stage pharmaceutical company with a singular focus on nicotine dependence. AchieveRx’s mission is to develop medicine for people who want to quit smoking or vaping. That medicine is cytisinicline, an investigational compound. Three ideas guide the Company: simplicity, science, and second chances, for good. To learn more, visit www.AchieveRx.com .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Achieve Life Sciences, Inc.’s Item 2.02 8-K filed November 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.